



@article {3275,
	title = {Biodistribution and pharmacokinetics of Dapivirine-loaded nanoparticles after vaginal delivery in mice},
	journal = {Pharmaceutical Research},
	volume = {31},
	year = {2014},
	note = {Cited By (since 1996):2Export Date: 21 November 2014},
	month = {2014},
	pages = {1834 - 1845},
	abstract = {Purpose: To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Methods: Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. Results: PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Conclusions: Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis. {\textcopyright} 2014 Springer Science+Business Media New York.},
	keywords = {HIV/AIDS, microbicides, poly(ε-caprolactone), pre-exposure prophylaxis, vaginal drug delivery},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84904252215\&partnerID=40\&md5=e50091fa44bc3ac794251baa9e57d736},
	author = {Das Neves, J. and Ara{\'u}jo, F. and Andrade, F. and Amiji, M. and Bahia, M.F. and Sarmento, B.}
}
@article {3286,
	title = {Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system},
	journal = {International Journal of Nanomedicine},
	volume = {9},
	year = {2014},
	note = {Export Date: 21 November 2014},
	month = {2014},
	pages = {1757 - 1769},
	abstract = {Antiretroviral drug therapy plays a cornerstone role in the treatment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome patients. Despite obvious advances over the past 3 decades, new approaches toward improved management of infected individuals are still required. Drug distribution to the central nervous system (CNS) is required in order to limit and control viral infection, but the presence of natural barrier structures, in particular the blood-brain barrier, strongly limits the perfusion of anti-HIV compounds into this anatomical site. Nanotechnology-based approaches may help providing solutions for antiretro-viral drug delivery to the CNS by potentially prolonging systemic drug circulation, increasing the crossing and reducing the efflux of active compounds at the blood-brain barrier, and providing cell/tissue-targeting and intracellular drug delivery. After an initial overview on the basic features of HIV infection of the CNS and barriers to active compound delivery to this anatomical site, this review focuses on recent strategies based on antiretroviral drug-loaded solid nanoparticles and drug nanosuspensions for the potential management of HIV infection of the CNS. {\textcopyright} 2014 Gomes et al.},
	keywords = {Blood-brain barrier, drug targeting, Efflux transporters, HIV/AIDS, Protease inhibitors},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84898486385\&partnerID=40\&md5=31d2c7f6e0759fb62143e329fb8599ae},
	author = {Gomes, M.J. and Das Neves, J. and Sarmento, B.}
}
